MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Mycophenolate (Cellcept®)

Selected References

  • Alsebayel MM, et al. 2018. Congenital esophageal atresia and microtia in a newborn secondary to mycophenolate mofeil exposure during pregnancy: A case report and review of the literature. Am J Case Rep 3(19) 523-526.
  • Boyle S, et al. 2021.Pregnancy following heart transplantation: A single centre case series and review of the literature. Heart Lung Circ.;30:144–53.
  • Coscia LA, et al. 2015. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet 4(2):42-55.
  • Egeberg A, et al 2017 Birth outcomes in children fathered by men treated with immunosuppressant drugs before conception-A Danish population-based cohort study. J Invest Dermatol.Aug;137(8):1790-1792. doi: 10.1016/j.jid.2017.03.030. Epub 2017 Apr 19. PMID: 28433544
  • Hoeltzenbein M, et al. 2012. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 158A(3):588-596.
  • Jones A, et al. 2013. Outcomes of pregnancies fathered by solid-organ transplant recipients exposed to mycophenolic acid products. 23(2)153-157.
  • Kim M, Rostas S, and Gabardi S. 2013. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. Am J Transplant 13(6):1383-1389.
  • King RW, et al. 2017. Pregnancy outcomes related to mycophenolate exposure in female kidney transplant recipients. Am J Transplant 17(1)151-160.
  • Martin MC et al. 2014. Esophageal atresia and prenatal exposure to mycophenolate. Reprod Toxicol 50:117-121, 2014.
  • Martin- Moreno PL, et al 2021. Paternal safety of the use of mycophenolic acid in kidney transplant recipients. Results of the EMVARON study. Clin Transplant 35(5): e14256. PMID: 33599030. DOI: 10.1111/ctr.14256.
  • Midtvedt K, et al. 2017. Exposure to mycophenolate and fatherhood. Transplantation 101(7) e214-217.
  • Perez-Aytes A, et al. 2017. Mycophenolate mofetil embryopathy: A newly recognized teratogenic syndrome. Eur J Med Genet 60(1):16-21.
  • Sifontis NM, et al. 2006. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82:1698-1702.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.